{{Rsnum
|rsid=17215333
|Gene=SLC25A5P8
|Chromosome=9
|position=32335141
|Orientation=plus
|GMAF=0.2066
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 52.2 | 43.4 | 4.4
| HCB | 81.8 | 17.5 | 0.7
| JPT | 85.8 | 14.2 | 0.0
| YRI | 59.2 | 37.4 | 3.4
| ASW | 63.2 | 29.8 | 7.0
| CHB | 81.8 | 17.5 | 0.7
| CHD | 82.6 | 16.5 | 0.9
| GIH | 41.6 | 50.5 | 7.9
| LWK | 61.8 | 33.6 | 4.5
| MEX | 52.6 | 43.9 | 3.5
| MKK | 75.6 | 23.1 | 1.3
| TSI | 49.0 | 45.1 | 5.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17215333
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109430
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17215333
|overall_frequency_n=31
|overall_frequency_d=128
|overall_frequency=0.242188
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=25
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | Affy GenomeWide 6}}